SCHEMBL13248271

SCHEMBL13248271

CCN(CC)c1ccc2cc(C(=O)NCCOCCO)c(=O)oc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.61
MEN1 O00255 6/20 0.61
ALDH1A1 P00352 5/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
MAPT P10636 4/20 0.61
KDM4E B2RXH2 4/20 0.61
MAOB P27338 3/20 0.61
ATM Q13315 3/20 0.61
HSD17B10 Q99714 3/20 0.61
HPGD P15428 2/20 0.61
USP2 O75604 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2C19 P33261 1/20 0.61
SLC16A3 O15427 1/20 0.61
ALOX15 P16050 1/20 0.61
SLC16A1 P53985 1/20 0.61
GBA1 P04062 1/20 0.61
NPC1 O15118 1/20 0.56
STAT3 P40763 1/20 0.56
STAT1 P42224 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13524273 0.93 ALDH1A1 (0.63) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL15298984 0.92 MAOB (0.63) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL13248269 0.91 KMT2A (0.60) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL14948237 0.90 KMT2A (0.59) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL13248272 0.90 ALDH1A1 (0.62) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3174736 0.90 KMT2A (0.65) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL9303724 0.89 KMT2A (0.70) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL9302597 0.88 KMT2A (0.62) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL14820431 0.87 KMT2A (0.67) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL17612195 0.87 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3247710-B1 COUMARIN-BASED COMPOUNDS AND RELATED METHODS BIOSEARCH TECH INC (US) 2022-10-19 EP disclosed
CN-107207480-B Coumarin-based compounds and related methods 生物检索技术股份有限公司 2021-06-25 CN disclosed
US-11034677-B2 Coumarin-based compounds and related methods BIOSEARCH TECHNOLOGIES, INC. (US) 2021-06-15 US disclosed
US-11034677-B2 Coumarin-based compounds and related methods BIOSEARCH TECHNOLOGIES, INC. (US) 2021-06-15 US disclosed
EP-3247710-A1 COUMARIN-BASED COMPOUNDS AND RELATED METHODS Biosearch Technologies, Inc. (US) 2017-11-29 EP disclosed
US-20170015652-A1 Coumarin-based compounds and related methods BIOSEARCH TECHNOLOGIES, INC. 2017-01-19 US disclosed
US-20170015652-A1 Coumarin-based compounds and related methods BIOSEARCH TECHNOLOGIES, INC. 2017-01-19 US disclosed
US-20170015652-A1 Coumarin-based compounds and related methods BIOSEARCH TECHNOLOGIES, INC. 2017-01-19 US disclosed
WO-2016118305-A1 COUMARIN-BASED COMPOUNDS AND RELATED METHODS BIOSEARCH TECHNOLOGIES, INC. (US) 2016-07-28 WO disclosed
WO-2016118305-A1 COUMARIN-BASED COMPOUNDS AND RELATED METHODS BIOSEARCH TECHNOLOGIES, INC. (US) 2016-07-28 WO disclosed
US-8846320-B2 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. (US) 2014-09-30 US disclosed
US-20100184087-A1 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. 2010-07-22 US disclosed
US-7695929-B2 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits VENTANA MEDICAL SYSTEMS, INC. (US) 2010-04-13 US disclosed
US-20080268462-A1 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits VENTANA MEDICAL SYSTEMS, INC. 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080268462-A1 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits HRH4, CRBN, NCDN KMT2A 3827/4885MEN1 4162/4885ALDH1A1 2096/4885
US-11034677-B2 Coumarin-based compounds and related methods HCCS, FBL, COIL KMT2A 3163/4885MEN1 2472/4885ALDH1A1 990/4885
US-20170015652-A1 Coumarin-based compounds and related methods HCCS, FBL, COIL KMT2A 3163/4885MEN1 2472/4885ALDH1A1 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.